• If you are wondering whether AnaptysBio's share price still lines up with its underlying worth, you are not alone. That is exactly what this article will unpack.
• AnaptysBio's stock most recently closed at US$47.90, with returns of 0.1% over 7 days, 9.1% over 30 days, 6.6% year to date, 197.9% over 1 year, 84.6% over 3 years and 45.1% over 5 years. This performance has naturally raised questions about how the current price compares to its fundamentals.
• Recent attention on AnaptysBio has been driven by ongoing interest in its pharmaceutical and biotech pipeline and how investors view its potential in that space. This has put more focus on whether the current market price is supported by the company’s assets, prospects and risk profile.
• Our valuation model currently gives AnaptysBio a value score of 3 out of 6, suggesting that some checks point to the shares looking inexpensive while others do not. Next we will walk through the key valuation methods behind that score before finishing with a way to assess value that goes beyond the headline numbers.

Approach 1: AnaptysBio Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company could be worth today by projecting its future cash flows and then discounting those projections back to the present. For AnaptysBio, the model used is a 2 Stage Free Cash Flow to Equity approach, which separates near term estimates from longer term projections.

On the latest numbers, AnaptysBio reported last twelve month free cash flow of a loss of $145.97 million. Analyst inputs and extrapolations then feed into a ten year path of free cash flow that moves from projected losses in the earlier years to a projected free cash flow of $137 million in 2030. Beyond the analyst horizon, Simply Wall St extends the series using its own growth assumptions.

When these projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $220.50 per share. At the recent share price of $47.90, this implies a 78.3% discount. On this DCF view, AnaptysBio appears significantly undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests AnaptysBio is undervalued by 78.3%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Approach 2: AnaptysBio Price vs Sales

For companies where earnings are not yet positive, P/S is often more useful than P/E because it focuses on what the market is paying for each dollar of revenue rather than profit, which can still be in a loss phase.

What investors usually consider a normal or fair P/S ratio depends on expectations for future growth and how risky the business model looks. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk tends to pull that multiple down.

AnaptysBio currently trades on a P/S of 7.83x, compared with the Biotechs industry average of 10.91x and a peer group average of 5.75x. Simply Wall St also calculates a Fair Ratio of 2.80x, which is its view of what a balanced P/S for AnaptysBio could look like after accounting for factors such as earnings growth profile, industry, profit margin, market cap and risk indicators.

This Fair Ratio can be more tailored than a simple peer or industry comparison because it blends those company specific inputs into one figure. When set against the current 7.83x P/S, the 2.80x Fair Ratio indicates that AnaptysBio is trading above that level.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies.

Upgrade Your Decision Making: Choose your AnaptysBio Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. Narratives let you tell a clear story about AnaptysBio by linking your view of its future revenues, earnings and margins to a forecast and then to your own fair value estimate.

On Simply Wall St’s Community page, used by millions of investors, you can create or follow Narratives that set out assumptions in plain language, attach them to a simple financial model, and then compare the resulting Fair Value to the current market price. This can help you decide whether you see AnaptysBio as more attractive or less attractive at today’s level.

Because Narratives update automatically when new information such as earnings releases or major news flows through, your fair value view keeps in step with the latest data without you needing to rebuild the whole model.

For example, one AnaptysBio Narrative might assume very optimistic revenue growth and profitability that supports a much higher fair value. Another might assume more cautious revenue expectations and margins that point to a fair value closer to the recent share price.

Do you think there's more to the story for AnaptysBio? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.